SE9502474D0 - Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa - Google Patents

Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa

Info

Publication number
SE9502474D0
SE9502474D0 SE9502474A SE9502474A SE9502474D0 SE 9502474 D0 SE9502474 D0 SE 9502474D0 SE 9502474 A SE9502474 A SE 9502474A SE 9502474 A SE9502474 A SE 9502474A SE 9502474 D0 SE9502474 D0 SE 9502474D0
Authority
SE
Sweden
Prior art keywords
cancerous diseases
prevention
treatment
preparation
pharmaceutical compositions
Prior art date
Application number
SE9502474A
Other languages
English (en)
Other versions
SE521049C2 (sv
SE9502474L (sv
Inventor
Gyula Kulcsar
Original Assignee
Immunal Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunal Kft filed Critical Immunal Kft
Publication of SE9502474D0 publication Critical patent/SE9502474D0/sv
Publication of SE9502474L publication Critical patent/SE9502474L/sv
Publication of SE521049C2 publication Critical patent/SE521049C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9502474A 1993-11-09 1995-07-06 Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa SE521049C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
PCT/HU1994/000049 WO1995013061A1 (en) 1993-11-09 1994-11-08 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation

Publications (3)

Publication Number Publication Date
SE9502474D0 true SE9502474D0 (sv) 1995-07-06
SE9502474L SE9502474L (sv) 1995-07-06
SE521049C2 SE521049C2 (sv) 2003-09-23

Family

ID=10984131

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502474A SE521049C2 (sv) 1993-11-09 1995-07-06 Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa

Country Status (18)

Country Link
EP (1) EP0679081B1 (sv)
JP (1) JPH08508045A (sv)
KR (1) KR100363779B1 (sv)
CN (1) CN1128615C (sv)
AT (1) AT408414B (sv)
AU (1) AU682735B2 (sv)
CA (1) CA2151826C (sv)
CH (1) CH686867A5 (sv)
CZ (1) CZ286633B6 (sv)
DE (2) DE4498692T1 (sv)
ES (1) ES2094702B1 (sv)
FI (1) FI953369A (sv)
HU (1) HU213677B (sv)
NL (1) NL195007C (sv)
PL (1) PL177981B1 (sv)
RU (1) RU2138257C1 (sv)
SE (1) SE521049C2 (sv)
WO (1) WO1995013061A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
AU6340198A (en) * 1997-03-04 1998-09-22 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resultingin chronic conditions
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
JPWO2003030890A1 (ja) * 2001-10-05 2005-02-10 哲朗 浅尾 免疫系活性化剤
EP1583543A4 (en) * 2002-01-16 2009-09-09 Eliezer Rapaport METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
US10016385B2 (en) * 2004-12-17 2018-07-10 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
EP1909804B1 (en) * 2005-08-03 2012-02-29 National Cancer Center Glucosamine and derivatives thereof useful as transglutaminase inhibitors in the treatment of a nervous system disorder
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
WO2015137383A1 (ja) * 2014-03-11 2015-09-17 味の素株式会社 癌化学療法の補助剤
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (sv) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability

Also Published As

Publication number Publication date
DE4498692T1 (de) 1996-02-22
SE521049C2 (sv) 2003-09-23
EP0679081A1 (en) 1995-11-02
FI953369A0 (sv) 1995-07-07
EP0679081B1 (en) 2002-02-06
KR100363779B1 (ko) 2003-03-06
CN1116406A (zh) 1996-02-07
HU213677B (en) 1997-12-29
DE69429806D1 (de) 2002-03-21
CZ177395A3 (en) 1996-01-17
RU2138257C1 (ru) 1999-09-27
ATA900894A (de) 2001-04-15
FI953369A (sv) 1995-07-07
AU682735B2 (en) 1997-10-16
ES2094702B1 (es) 1998-02-16
SE9502474L (sv) 1995-07-06
AU1074995A (en) 1995-05-29
PL309600A1 (en) 1995-10-30
CN1128615C (zh) 2003-11-26
CA2151826A1 (en) 1995-05-18
CA2151826C (en) 2008-06-17
DE69429806T2 (de) 2002-09-12
NL195007C (nl) 2003-06-10
CZ286633B6 (cs) 2000-05-17
NL9420013A (nl) 1995-10-02
WO1995013061A1 (en) 1995-05-18
ES2094702A1 (es) 1997-01-16
HU9303171D0 (en) 1994-01-28
JPH08508045A (ja) 1996-08-27
PL177981B1 (pl) 2000-02-29
CH686867A5 (de) 1996-07-31
AT408414B (de) 2001-11-26

Similar Documents

Publication Publication Date Title
SE9502474D0 (sv) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
MY130035A (en) Antiviral compounds
MY107843A (en) Anti-viral compounds.
WO1996013512A3 (en) L-ribofuranosyl nucleosides
EP1140840A4 (en) DIPHENYLUREA WITH SUBSTITUENTS -G (V) -CARBOXYARYLES, INHIBITORS OF RAF KINASE
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
MXPA04012965A (es) Inhibidores virales.
EP0375329A3 (en) Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
MX9606732A (es) Compuestos terapeuticos.
DE69624340D1 (de) Pharmazeutische zusammensetzung zur behandlung von herpes
NZ305855A (en) Sugar modified cytostatic derivatives and their use in antitumour compositions
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
MX9702926A (es) L-eritrosilnucleosidos.
IE893080L (en) Novel 2'-halomethylidene,2'-ethenylidene and¹2'-ethynyl adenosine derivatives
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
GB9505082D0 (en) Medicament
EP0346108A3 (en) Anti-infective nucleosides
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
ES2170377T3 (es) Composicion que contiene quitosana.
IL92402A0 (en) Pyrimidine nucleoside derivatives,their preparation and pharmaceutical compositions containing them
IL107818A (en) Pharmaceutical compositions for treating viral infections by conjunctive therapy with acylovir-like compounds and a 2'-(halo) methylene nucleoside analog

Legal Events

Date Code Title Description
NUG Patent has lapsed